(Q68032505)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1516252%20AND%20SRC:MED&resulttype=core&format=json

20 September 2019

title

Characterization of anti-interferon-alpha antibodies appearing during recombinant interferon-alpha 2a treatment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1516252%20AND%20SRC:MED&resulttype=core&format=json

20 September 2019

author name string

L E Rönnblom

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1516252%20AND%20SRC:MED&resulttype=core&format=json

20 September 2019

E T Janson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1516252%20AND%20SRC:MED&resulttype=core&format=json

20 September 2019

A Perers

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1516252%20AND%20SRC:MED&resulttype=core&format=json

20 September 2019

K E Oberg

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1516252%20AND%20SRC:MED&resulttype=core&format=json

20 September 2019

G V Alm

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1516252%20AND%20SRC:MED&resulttype=core&format=json

20 September 2019

publication date

1 September 1992

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1516252%20AND%20SRC:MED&resulttype=core&format=json

Clinical and Experimental Immunology

20 September 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1516252%20AND%20SRC:MED&resulttype=core&format=json

20 September 2019

volume

89

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1516252%20AND%20SRC:MED&resulttype=core&format=json

20 September 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1516252%20AND%20SRC:MED&resulttype=core&format=json

20 September 2019

page(s)

330-335

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1516252%20AND%20SRC:MED&resulttype=core&format=json

Large-scale Production of Human Leukocyte Interferon Containing 108 Units per ml

20 September 2019

cites work

1 reference

12 December 2020

Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon alfa-2a by intramuscular injection

1 reference

12 December 2020

Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations

1 reference

12 December 2020

Spontaneous interferon-alpha antibodies in a patient with pure red cell aplasia and recurrent cutaneous carcinomas

1 reference

12 December 2020

Interferon-induced enhancement of 2',5'-oligoadenylate synthetase in mid-gut carcinoid tumours

1 reference

12 December 2020

Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors

1 reference

12 December 2020

Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy

1 reference

12 December 2020

Treatment of malignant carcinoid tumors with human leukocyte interferon: long-term results

1 reference

12 December 2020

Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity

1 reference

12 December 2020

Detection of anti-interferon-alpha 2a antibodies in chronic liver disease

1 reference

12 December 2020

Effects of interferon-gamma and tumor necrosis factor-alpha on macrophage enzyme levels

1 reference

12 December 2020

Interferon antibodies in patients with chronic HBV infection treated with recombinant interferon

1 reference

12 December 2020

Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon

1 reference

12 December 2020

Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies

1 reference

12 December 2020

Different induction patterns of mRNA for IFN-alpha and -beta in human mononuclear leukocytes after in vitro stimulation with herpes simplex virus-infected fibroblasts and Sendai virus

1 reference

12 December 2020

Autoimmune thyroid disease in interferon-treated patients

1 reference

12 December 2020

Clinical significance of anti-IFN-alpha antibody titres during interferon therapy

1 reference

12 December 2020

Simple and rapid determination of 5-hydroxyindole-3-acetic acid in urine by direct injection on a liquid chromatographic column

1 reference

12 December 2020

Effects of Leukocyte Interferon on Clinical Symptoms and Hormone Levels in Patients with Mid-Gut Carcinoid Tumors and Carcinoid Syndrome

1 reference

12 December 2020

Possible induction of systemic lupus erythematosus by interferon-α treatment in a patient with a malignant carcinoid tumour

1 reference

12 December 2020

10.1111/J.1365-2249.1992.TB06957.X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1516252%20AND%20SRC:MED&resulttype=core&format=json

20 September 2019

1 reference